Breaking News Instant updates and real-time market news.

AVAV

AeroVironment

$76.52

-0.37 (-0.48%)

, AMBA

Ambarella

$40.57

0.44 (1.10%)

19:04
03/05/19
03/05
19:04
03/05/19
19:04

Fly Intel: After Hours Movers

UP AFTER EARNINGS: AeroVironment (AVAV) up 11.0%... Ambarella (AMBA) up 7.2%... PlayAGS (AGS) up 3.1%... Quanex Building (NX) up 2.8%... Cooper Companies (COO) up 1.7%... Ziopharm (ZIOP) up 1.4%... Kura Oncology (KURA) up 1.3%. DOWN AFTER EARNINGS: Qutoutiao (QTT) down 13.9%... Nio Inc (NIO) down 12.6%... Vivint Solar (VSLR) down 8.9%... Cardlytics (CDLX) down 7.9%... Urban Outfitters (URBN) down 4.3%... United Natural Foods (UNFI) down 3.4%... Ross Stores (ROST) down 2.9%. ALSO LOWER: CymaBay Therapeutics (CBAY) down 4.4% after equity offering... Horizon Pharma (HZNP) down 2.5% after disclosing civil investigative demand Bandwidth... (BAND) down 2.0% after equity offering... Exact Sciences (EXAS) down 1.0% after convertible note offering. Movers as of 18:30ET.

AVAV

AeroVironment

$76.52

-0.37 (-0.48%)

AMBA

Ambarella

$40.57

0.44 (1.10%)

AGS

PlayAGS

$24.24

0.5 (2.11%)

NX

Quanex

$17.01

-0.205 (-1.19%)

COO

Cooper Companies

$290.40

2.59 (0.90%)

ZIOP

Ziopharm

$2.96

0.26 (9.63%)

KURA

Kura Oncology

$14.89

-0.18 (-1.19%)

QTT

Qutoutiao

$15.63

1.87 (13.59%)

NIO

NIO Inc.

$10.12

0.32 (3.27%)

VSLR

Vivint Solar

$5.27

-0.085 (-1.59%)

CDLX

Cardlytics

$18.42

0.29 (1.60%)

URBN

Urban Outfitters

$30.39

0.18 (0.60%)

UNFI

United Natural Foods

$15.03

-0.11 (-0.73%)

ROST

Ross Stores

$94.18

0.58 (0.62%)

CBAY

CymaBay

$13.31

-0.1 (-0.75%)

HZNP

Horizon Pharma

$27.22

-0.78 (-2.79%)

BAND

Bandwidth

$57.75

0.88 (1.55%)

EXAS

Exact Sciences

$87.62

-1.29 (-1.45%)

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

  • 12

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 19

    Mar

  • 25

    Mar

  • 28

    Mar

  • 16

    Apr

  • 17

    Apr

  • 18

    May

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

AVAV AeroVironment
$76.52

-0.37 (-0.48%)

11/30/18
PIPR
11/30/18
NO CHANGE
Target $78
PIPR
Neutral
AeroVironment shares fully valued at current levels, says Piper Jaffray
AeroVironment reported fiscal Q3 results with revenues below and earnings above Street expectations, Piper Jaffray analyst Troy Jensen tells investors in a research note. The analyst continues to believe the company's largest growth opportunity is from sales to international governments. He remains bullish on AeroVironment's long-term opportunities but thinks a "lot of this optimism" is currently priced into the stock. Jensen raised his price target for the shares to $78 from $77 and reiterates a Neutral rating on the name. He finds AeroVironment fully valued at current levels.
01/24/19
WBLR
01/24/19
INITIATION
WBLR
Outperform
William Blair starts AeroVironment at Outperform on drone spending growth
William Blair analyst Louie DiPalma last night initiated coverage of AeroVironment with an Outperform rating. According to an analysis by the Center for the Study of the Drone at Bard College, the U.S. Department of Defense requested $8.9B for unmanned systems in the government's fiscal 2019 budget, DiPalma tells investors in a research note. Annual growth for the U.S. fiscal year drone budget allocation accelerated to 20%, with a 14.7% five-year annual growth rate, adds the analyst. He points out that AeroVironment is the industry leader in small unmanned aerial systems for military users. DiPalma sees the shares trading to a range of $82 to $105 over the next 18 months. He expects defense budget drone spending growth to continue to exceed overall defense budget growth by a wide margin.
01/24/19
01/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apergy (APY) initiated with a Buy at Gabelli. 2. Corporacion America Airport (CAAP) assumed with a Buy at Goldman Sachs. 3. Credit Acceptance (CACC) initiated with a Sell at BTIG. 4. AeroVironment (AVAV) initiated with an Outperform at William Blair. 5. Zendesk (ZEN) initiated with a Perform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/24/19
WBLR
01/24/19
INITIATION
WBLR
Outperform
AeroVironment initiated with an Outperform at William Blair
William Blair started AeroVironment with an Outperform rating saying the company is the leading provider of small military drones.
AMBA Ambarella
$40.57

0.44 (1.10%)

01/14/19
NEED
01/14/19
NO CHANGE
NEED
Hold
Needham more positive on Ambarella processors after CES
Needham analyst N. Quinn Bolton kept his Hold rating on Ambarella after its CES presentations, saying that while the meetings have highlighted a "cautious demand environment" in the industry, he has turned more "positive on the maturity of the company's CVflow". The analyst notes that the combined third party software running on Ambarella 's CV22 processors "offered similar detection and classification performance to competing systems at very low power levels", adding that he was also "impressed with the company's stereo camera based demonstrations for both near-field and far-field object detection and depth perception."
10/29/18
NORL
10/29/18
INITIATION
Target $38
NORL
Outperform
Ambarella initiated with an Outperform at Northland
Northland analyst Gus Richard initiated Ambarella with a Buy and $38 price target saying it is well positioned for growth of Computer Vision. Richard sees multiple catalysts over the next 12 months including the ramp of Computer Vision Products in 1H 2019, adoption in Security Camera market, automotive design wins, and reduced Consumer revenue headwinds.
08/31/18
MSCO
08/31/18
NO CHANGE
Target $50
MSCO
Overweight
Morgan Stanley bullishness on Ambarella computer vision opportunity still intact
Morgan Stanley analyst Joseph Moore said a large miss in Ambarella's consumer business, an auto program delay and trade tensions in surveillance will all likely test investor patience, but he remains bullish as his enthusiasm for the new computer vision opportunity has not waned. He thinks the company is hitting its milestones and still expects the company to be able to talk more specifically about autonomous driving customers later this year, Moore tells investors. While his view of the upside has not changed, the downside protection in the event that the company is less successful transitioning to computer vision has declined, added Moore, who keeps an Overweight rating on Ambarella shares but lowered his price target to $50 from $58.
11/30/18
ROTH
11/30/18
NO CHANGE
Target $40
ROTH
Neutral
Ambarella price target raised to $40 from $35 at Roth Capital
Following Ambarella's Q3 results, Roth Capital analyst Suji Desilva said he believes the name represents a differentiated investment opportunity in low power video and computer vision processor. While revenue from newer CV products remains an intermediate-term opportunity, Desilva says he is encouraged by initial design wins in both surveillance and automotive. While he raises his price target to $40, he remains Neutral and will look for additional computer vision traction prior to getting more constructive in the name.
AGS PlayAGS
$24.24

0.5 (2.11%)

08/23/18
08/23/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Huntington Ingalls (HII) initiated with a Neutral at Seaport Global. 2. Plug Power (PLUG) initiated with an Outperform at Oppenheimer. 3. On Deck Capital (ONDK) initiated with a Buy at B. Riley FBR. 4. PlayAGS (AGS) initiated with an Outperform at Telsey Advisory. 5. WMIH (WMIH) initiated with an Outperform at Wedbush. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/16/18
JEFF
11/16/18
NO CHANGE
JEFF
Jefferies sees long-term investment opportunities in Gaming
The "profound weakness" in Gaming stocks has created dislocation which presents long-term investment opportunities, Jefferies analyst David Katz tells investors in a research note titled "'Buy On Weakness' Is Not Enough." The analyst says his "broad view" of asset value, leadership execution and capital structure risk lead to him focus on his top picks, Eldorado Resorts (ERI) and International Game Technology (IGT). He also has Buy ratings on Boyd Gaming (BYD), PlayAGS (AGS) and Everi Holdings (EVRI).
10/01/18
RHCO
10/01/18
INITIATION
Target $35
RHCO
Buy
PlayAGS assumed with a Buy at SunTrust
SunTrust analyst Barry Jonas assumed PlayAGS with a Buy rating and a price target of $35 as part of his broader "U.S. Gaming" coverage transfer research report. The analyst is positive on the company's current product pipeline and benefits from the new slot machines helping it expand market share from a low base.
10/11/18
JEFF
10/11/18
NO CHANGE
JEFF
International Game, Everi pullbacks bring buying opportunity, says Jefferies
After attending the Global Gaming Expo, Jefferies analyst David Katz believes "broadly stronger" product offerings should be positive for Gaming stocks. The recent weakness in shares of International Game Technology (IGT) and Everi Holdings (EVRI), who both have "strong prospects," present buying opportunities, Katz tells investors in research note. He also believes PlayAGS' (AGS) relative outperformance is justified as its "growth opportunities warrant the premium multiple." Further, the analyst thinks Scientific Games (SGMS) has been overly pressured by a series of negative catalysts, "all of which should stabilize in time." The company's products "are too good for the shares' decline not to correct," Katz contends.
NX Quanex
$17.01

-0.205 (-1.19%)

06/08/18
SIDC
06/08/18
DOWNGRADE
SIDC
Neutral
Quanex downgraded to Neutral from Buy at Sidoti
06/08/18
06/08/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Petrobras (PBR) downgraded to Neutral from Buy at UBS with analyst Luiz Carvalho citing reduced visibility on its long-term pricing policy after the company recently reduced prices, which significantly lowered the chances of the company selling its refining assets, keeping it a monopoly, and exposed it to possible interference depending on the government's policy approach and macro conditions. 2. Domino's Pizza (DPZ) downgraded to Hold from Buy at Maxim with analyst Stephen Anderson saying the company's comp performance and market share gains in the U.S., accelerated unit development worldwide, and mostly favorable cost outlook warrant a premium multiple, but believes these positives have been priced into shares. 3. Noble Energy (NBL) downgraded to Hold from Buy at Tudor Pickering. 4. Sientra (SIEN) downgraded to Hold from Buy at Maxim with analyst Anthony Vendetti saying that while he is optimistic on Sientra's long-term prospects, the valuation is significantly ahead of peer averages and the stock price has exceeded his 12-month target. 5. Quanex (NX) downgraded to Neutral from Buy at Sidoti. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
COO Cooper Companies
$290.40

2.59 (0.90%)

02/01/19
SPHN
02/01/19
UPGRADE
Target $305
SPHN
Overweight
Cooper Companies upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Chris Cooley upgraded Cooper Companies to Overweight and raised his price target to $305 from $270. The analyst believes that the company is positioned to boost its earnings guidance, citing a stronger growth of its single-use daily SiH contact lens sales, above-forecast Paragard sales, and more modest FX-related headwinds than previously anticipated. Fooley adds that the current investor sentiment is "mixed at best", which could lead to valuation lift in the near term.
02/01/19
02/01/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. United Technologies (UTX) upgraded to Conviction Buy from Buy at Goldman Sachs. 2. Eldorado Gold (EGO) upgraded to Outperform from Sector Perform at National Bank and to Outperform from Market Perform at BMO Capital. 3. Baxter (BAX) upgraded to Equal Weight from Underweight at Barclays with analyst Kristen Stewart saying over the past three months, expectations for the company have been reset, making a neutral rating more appropriate. The analyst also raised her price target for the shares to $72 from $67. 4. Cooper Companies (COO) upgraded to Overweight from Equal Weight at Stephens with analyst Chris Cooley saying he believes that the company is positioned to boost its earnings guidance, citing a stronger growth of its single-use daily SiH contact lens sales, above-forecast Paragard sales, and more modest FX-related headwinds than previously anticipated. 5. Allegiant Travel (ALGT) upgraded to Outperform from In-Line at Imperial Capital with analyst Michael Derchin saying he views the shares as attractive after the company's fiscal 2019 earnings outlook came in well ahead of his expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/01/19
SPHN
02/01/19
UPGRADE
SPHN
Overweight
Cooper Companies upgraded to Overweight from Equal Weight at Stephens
01/04/19
GSCO
01/04/19
DOWNGRADE
Target $221
GSCO
Sell
Cooper Companies downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Isaac Ro downgraded Cooper Companies to Sell and lowered his price target for the shares to $221 from $233. The analyst sees 2019 as an investment year for the company with downside risk to estimates due to a weaker macro environment and increasing competitive pressures in CooperVision.
ZIOP Ziopharm
$2.96

0.26 (9.63%)

06/19/18
HCWC
06/19/18
NO CHANGE
Target $5.5
HCWC
Buy
Ziopharm selloff brings buying opportunity, says H.C. Wainwright
The clinical hold placed on Ziopharm's third generation point-of-care CAR-T program is unlikely to bring a significant delay, H.C. Wainwright analyst Swayampakula Ramakanth tells investors in a research note. The analyst views yesterday's 18% share pullback as a buying opportunity and reiterates a Buy rating on Ziopharm with a $5.50 price target. He notes that neither of the Ziopharm's clinical programs on Ad-RTS-hIL-12 or second generation CD19 and CD33 CAR-Ts has been affected by the clinical hold. The clinical hold is more akin to the FDA putting a "pause" on the investigational new drug application review process while the company prepares the response, Ramakanth argues.
11/15/18
11/15/18
UPGRADE
Target $5

Outperform
Ziopharm upgraded to Outperform at Raymond James
As previously reported, Raymond James analyst Reni Benjamin upgraded Ziopharm to Outperform from Market Perform, with a $5 price target. The analyst notes that the company provided an update on its cell and gene therapy programs in a recent conference call, saying it has severed its relationship with Intrexon, eliminating $157M million in preferred stock and significantly simplifying its corporate structure. Additionally, Ziopharm said that in conjunction with Steven Rosenberg and the NCI, it plans to utilize the Sleeping Beauty neoantigen platform to generate patient specific TCRs, with the filing of an IND expected by year end 2018/early 2019, he pointed out, adding that a cash infusion of $50M from long-term investors should extend the company's cash runway to Q2 of 2020.
11/15/18
RAJA
11/15/18
UPGRADE
RAJA
Outperform
Ziopharm upgraded to Outperform from Market Perform at Raymond James
06/18/18
JPMS
06/18/18
DOWNGRADE
JPMS
Underweight
Ziopharm downgraded to Underweight from Neutral at JPMorgan
KURA Kura Oncology
$14.89

-0.18 (-1.19%)

12/03/18
PIPR
12/03/18
NO CHANGE
Target $25
PIPR
Overweight
Kura Oncology remains 'favorite smallcap oncology name', says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren kept his Overweight rating and $25 price target on Kura Oncology following the company's update on the development of tipifarnib in highly refractory PTCL patients where a significant association between CXCL12 expression and clinical benefit was observed. The analyst notes that the data were "particularly impressive given the patients' refractory states and importantly, one patient was even able to receive a potentially curative transplant". Van Buren further contends that Kura Oncology is positioned for $500M or more in long-term sales for tipifarnib in HRAS-driven cancers, adding that its "shares are significantly undervalued based on that opportunity alone".
01/07/19
PIPR
01/07/19
NO CHANGE
Target $235
PIPR
Overweight
Piper Jaffray views price paid for Loxo by Eli Lilly as fair
Piper Jaffray analyst Tyler Van Buren views the price of $235 per share paid by Eli Lilly (LLY) for Loxo Oncology (LOXO) as fair. The analyst says the price is near the $250-plus he previously thought was achievable in an acquisition scenario for Loxo. Other names in the precision medicine/oncology space that could be up today as a result of the buyout are Agios Pharmaceuticals (AGIO), ArQule (ARQL), Array BioPharma (ARRY), Blueprint Medicines (BPMC), Kura Oncology (KURA), Mirati Therapeutics (MRTX) and others, Van Buren tells investors in a research note. He raised his price target for Loxo Oncology to $235 from $200 and keeps an Overweight rating on the shares.
01/18/19
PIPR
01/18/19
NO CHANGE
Target $25
PIPR
Overweight
Kura Oncology shares remain 'significantly undervalued,' says Piper Jaffray
Kura Oncology today provided evidence that tipifarnib could be active in patients with no abdominal pain and/or nodal/liver met disease, both of which are associated with high CXCL12 expression, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst estimates tipifarnib's opportunity in the HRAS-driven head and neck squamous cell carcinomas opportunity alone is worth $500M-plus in peak sales. However, with the recent data in CXCL12-driven peripheral T-cell lymphomas presented and now potentially pancreatic cancer, these estimates "could be pushed significantly higher over time," Van Buren adds. He continues to believe Kura Oncology shares are "significantly undervalued" and keeps an Overweight rating on the name with a $25 price target.
11/09/18
11/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. RH (RH) initiated with an Overweight at JPMorgan. 2. Ascendis Pharma (ASND) initiated with an Outperform at Credit Suisse. 3. Kura Oncology (KURA) initiated with an Overweight at Piper Jaffray. 4. Equitrans Midstream (ETRN) initiated with a Buy at Jefferies. 5. Instructure (INST) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, Reference Link
QTT Qutoutiao
$15.63

1.87 (13.59%)

02/15/19
UBSW
02/15/19
DOWNGRADE
Target $13.5
UBSW
Neutral
Qutoutiao downgraded to Neutral from Buy at UBS
UBS analyst Jerry Liu downgraded Qutoutiao to Neutral from Buy, telling investors in a research note that the share price has almost tripled since mid-December, possibly attributable to the strong momentum of the company's user expansion as well as Midu's initial success. Liu, who raised his price target to $13.50 from $11, says Qutoutiao's current price implies 2.8x2019E P/S, which he thinks represents a fair risk-reward balance between its user growth potential and margin pressure.
11/14/18
DBAB
11/14/18
UPGRADE
Target $8.1
DBAB
Buy
Qutoutiao upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Hanjoon Kim upgraded Qutoutiao to Buy while lowering his price target for the shares to $8.10 from $8.30. The analyst sees encouraging key performance indicators in the company's Q3 results.
02/15/19
UBSW
02/15/19
DOWNGRADE
UBSW
Neutral
Qutoutiao downgraded to Neutral from Buy at UBS
02/20/19
DBAB
02/20/19
DOWNGRADE
DBAB
Hold
Qutoutiao downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Hanjoon Kim downgraded Qutoutiao to Hold saying the risk/reward is balanced at current share levels.
NIO NIO Inc.
$10.12

0.32 (3.27%)

10/22/18
FBCO
10/22/18
INITIATION
Target $12.6
FBCO
Outperform
Credit Suisse starts NIO Inc. with an Outperform rating, $12.60 price target
Credit Suisse analyst Bin Wang initated NIO Inc. with an Outperform rating and $12.60 price target, stating that the company has a well-establish premium branding in China and is a leader in smart electric vehicle technology. He estimates NIO's revenue will grow at a 192% CAGR to 2020 and sees the company achieving its first year of breakeven in 2021, when Wang assumes it will be able to produce 165,000 units.Target $12.60.
01/15/19
EGHT
01/15/19
INITIATION
EGHT
Sell
86 Research starts NIO Inc. with a Sell rating, $4.70 price target
86 Research analyst Robert Cowell initiated coverage of NIO Inc. (NIO) with a Sell rating and $4.70 price target, stating that the company offers "attractive" fully electric SUVs at "attractive" prices in China, but is "losing large sums of money by doing so." He has concerns that NIO's operations are not efficient enough and said it does not have the same potential to revolutionize EV manufacturing as Tesla (TSLA) does. Additionally, the company's price advantage for its SUVs over Tesla cars is reliant on government subsidies, noted Cowell.
11/06/18
SBSH
11/06/18
NO CHANGE
Target $7.2
SBSH
Neutral
Citi sees three catalysts in three months for shares of NIO
Citi analyst Jeff Chung views NIO Inc.'s Q3 results as generally in-line with consensus and says its Q4 revenue only needs to achieve 70% quarter-over-quarter growth in order to meet his fiscal 2018 forecast, which he believes "carries very high visibility now." The analyst sees three catalysts for the shares in the next months. The first being December ES8 sales and production run-rate accelerating to 30,000 units from November's 23,000-25,000 units. The second being NIO announcing ES6 order backlog status between the end of fiscal 2018 and January 2019. And the third being the company's Q4 earnings report in February 2019. In a best case scenario, Chung expects Q4 revenue up 85% to 110% quarter-over-quarter. He keeps a Neutral rating on NIO Inc. with a $7.20 price target.
01/15/19
EGHT
01/15/19
INITIATION
Target $4.7
EGHT
Sell
NIO Inc. initiated with a Sell at 86 Research
86 Research initiated NIO Inc with a Sell adn $4.70 price target.
VSLR Vivint Solar
$5.27

-0.085 (-1.59%)

01/07/19
SBSH
01/07/19
INITIATION
Target $4.25
SBSH
Neutral
Vivint Solar initiated with a Neutral at Citi
Citi analyst Praful Mehta started Vivint Solar with a Neutral rating and $4.25 price target.
08/08/18
08/08/18
UPGRADE
Target $11

Outperform
Vivint Solar upgraded to Outperform on cash generation at JMP Securities
As previously reported, JMP Securities analyst Joseph Osha upgraded Vivint Solar to Outperform from Market Perform, stating that its operational performance has been solid and its September quarter installations guidance indicates that bookings conversion is good. More importantly, Vivint appears to have turned the corner on several of its financing challenges and is demonstrating that they are able to generate cash, said Osho, who set an $11 price target on the shares.
07/18/18
GSCO
07/18/18
DOWNGRADE
Target $15
GSCO
Neutral
Sunrun downgraded to Neutral at Goldman Sachs on valuation
As reported earlier, Goldman Sachs analyst Brian Lee downgraded Sunrun to Neutral from Buy as part of his broader research note on the solar sector and also kept his price target at $15 citing valuation on the stock. The analyst states that Sunrun has already run up 160% year to date and also cites the shift in China's solar policy in late May along with the ensuing price collapse across the supply chain toward quarter-end, which raises the risk of margin misses and weaker Q3 guidance. Lee adds that China-levered names like Jinko Solar (JKS) and Canadian Solar (CSIQ) thus face particularly challenging demand outlooks. The analyst has the most constructive view on the U.S. residential installer Vivint Solar (VSLR), which stands to "benefit from lower module costs and what we expect could close the valuation gap relative to peers.
08/08/18
JMPS
08/08/18
UPGRADE
JMPS
Outperform
Vivint Solar upgraded to Outperform from Market Perform at JMP Securities
CDLX Cardlytics
$18.42

0.29 (1.60%)

03/06/18
RHCO
03/06/18
INITIATION
Target $25
RHCO
Buy
Cardlytics initiated with a Buy at SunTrust
SunTrust analyst Youssef Squali initiated Cardlytics (CDLX) with a Buy rating and a price target of $25. Squali contends that the discount with which this "leader in the $11B native ad bank market trade" should close once investors become familiar with its "limited inventory, large partnerships and lack of easily identifiable publicly-traded comps", looking beyond the company's longer sales cycle. The analyst also points to Cardlytics pilot partnership with Wells Fargo (WFC) in first party data collection, which could roll out nationwide in 2019 and create more significant revenue growth.
03/06/18
03/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Becton Dickinson (BDX) initiated with a Market Perform at BMO Capital. 2. Cardlytics (CDLX) initiated with a Buy at SunTrust, an Overweight at JPMorgan and KeyBanc, a Neutral at BofA/Merrill, and an Outperform at Wells Fargo. 3. iRhythm (IRTC) initiated with an Outperform at BMO Capital. 4. Genocea (GNCA) initiated with an Overweight at Cantor Fitzgerald. 5. Domino's Pizza (DPZ) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/18
RHCO
12/13/18
NO CHANGE
Target $27
RHCO
Buy
Cardlytics insider selling due to better than expected MAU growth, says SunTrust
SunTrust analyst Youssef Squali noted that Cardlytics has disclosed a series of triggered insider sales in recent days, but points out that a footnote to the filings makes clear that one of the criteria needed to trigger the accelerated vesting was that MAUs exceeded 85M for a given month. The analyst, who suspects that the period in question is November, noted that 85M MAUs hinted at in the filing tops his Q4 estimate of 63M and the consensus estimate of 64.4M. MAU growth creates more ad inventory and is a precursor to revenue growth, said Squali, who has a Buy rating and $27 price target on Cardlytics shares.
01/15/19
01/15/19
UPGRADE
Target $22

Buy
Cardlytics upgraded to Buy following guidance at BofA/Merrill
As previously reported, BofA/Merrill upgraded Cardlytics to Buy from Neutral and raised its price target to $22 from $18 following the positive Q4 preannouncment. Analyst Nat Schindler believes Cardlytics is beginning to reach scale with the user base and expects advertisers will continue to target its deep ad inventory. Schindler expects 2019 revenues to accelerate and sees long-term EBITDA margins of 25% as possible.
URBN Urban Outfitters
$30.39

0.18 (0.60%)

01/09/19
01/09/19
UPGRADE
Target $44

Overweight
Morgan Stanley upgrades Urban Outfitters to Overweight on fashion shift
As previously reported, Morgan Stanley analyst Kimberly Greenberger upgraded Urban Outfitters to Overweight from Equal Weight, stating that she would use the 23% pullback since the end of Q3 as an entry point into the stock. The current fashion shift looks to be at an early stage and favors Urban's brands more than its specialty peers, according to Greenberger. Morgan Stanley's recent polling of 2,000 teens and adults to determine apparel purchase drivers and future intentions support Urban's fashion credibility, noted the analyst. Additionally, the fast supply chain bolsters Urban's merchandising strategy and she expects inventory best practices to support merchandise margins at all three of its brands, Greenberger said. She maintains a $44 price target on Urban Outfitters shares.
01/09/19
MSCO
01/09/19
UPGRADE
MSCO
Overweight
Urban Outfitters upgraded to Overweight from Equal Weight at Morgan Stanley
01/09/19
MSCO
01/09/19
NO CHANGE
MSCO
Morgan Stanley says Amazon may be near ceiling with current apparel offering
Morgan Stanley analyst Kimberly Greenberger reports that the firm's apparel survey showed that 72% of consumers purchased apparel on Amazon (AMZN) in the past 6 months, up from 69% last year. While this suggests Amazon continues to take apparel market share, the fact that the figure had jumped by 11% from 2016 to 2017 shows its gains may have slowed, said Greenberger, who noted that survey data and analysis suggest this may be due to Amazon seeing less success in fashion apparel versus its traction in apparel basics. Amazon ranked third lowest in terms of perception of offering "fashionable" clothing out of the more than 30 retailers surveyed, with only Walmart (WMT) and Costco (COST) ranked lower, noted Greenberger, who believes a lack of fashion success does not preclude Amazon from becoming the number one apparel market share player but could limit its long-term share gains. The fact that fashion "may be a more difficult code to crack" may also mean that traditional apparel retailers who lead in fashion credibility or low-price can better survive long-term, added the analyst. As previously reported, Greenberger upgraded Urban Outfitters (URBN) to Overweight this morning, in part due to its "fashion authority."
01/11/19
JEFF
01/11/19
NO CHANGE
Target $58
JEFF
Buy
Urban Outfitters comp solid, but not enough to change story, says Jefferies
Jefferies analyst Janine Stichter says that while Urban Outfitters's holiday company was "solid" at 5%, the number is probably not enough to change the near-term story for investors who are wary of potentially decelerating fundamentals. However, the analyst continues to see opportunity ahead for Urban Outfitters, fueled by "strong" execution, demand for new fashion trends, and growth across international, wholesale, and new categories. The current valuation is attractive with shares at "trough multiples," Stichter tells investors in a research note. She keeps a Buy rating on Urban Outfitters with a $58 price target.
UNFI United Natural Foods
$15.03

-0.11 (-0.73%)

01/10/19
RBCM
01/10/19
INITIATION
Target $25
RBCM
Outperform
SpartanNash initiated with an Outperform at RBC Capital
RBC Capital analyst Bill Kirk initiated SpartanNash (SPTN) with an Outperform rating and a price target of $25, citing the "volume opportunity" from the integration of United Natural Foods (UNFI) with Supervalu (SVU). The analyst says that the deal should allow SpartanNash market share performance in Food Distribution to improve. Kirk further contends that improvement in food PPI data, which turned positive for the first time in 7 months, is not reflected in the current consensus for SpartanNash, while the headwinds related to freight costs are expected to ease.
12/11/18
ARGS
12/11/18
DOWNGRADE
ARGS
Hold
United Natural Foods downgraded to Hold at Argus on slowing sales, higher costs
As reported earlier, Argus analyst Deborah Ciervo downgraded United Natural Foods to Hold based on her weaker outlook for the stock. The analyst says the company is "posting slower sales amid increased competition" and has also faced more pressure from "higher labor and freight costs, supply-chain issues, and a weaker product mix." Ciervo also slashes her FY19 EPS view on United Natural Foods to $1.76 from $3.45 based on the management's latest outlook along with her expectations of lower margins and higher interest / SG&A expenses next year. She adds that she would consider returning the stock's rating to Buy if the company's costs moderate and margins improve.
01/17/19
RBCM
01/17/19
NO CHANGE
Target $20
RBCM
United Natural Foods price target lowered to $20 from $24 at RBC Capital
RBC Capital analyst William Kirk lowered his price target on United Natural Foods (UNFI) to $20 and kept his Sector Perform rating after its ICR conference presentation. The analyst notes that while the discussions supported his view of "favorable macro trends" in terms of freight, gas, and inflation costs, he is concerned with the risk around the company's "out-year synergies" around the integration of its Supervalu acquisition. Kirk further warns that Amazon (AMZN) Whole Foods combination has the "ability, incentive, and precedent history to de-emphasize" United Natural Foods business.
12/11/18
PIVT
12/11/18
UPGRADE
Target $14
PIVT
Hold
United Natural Foods upgraded to Hold from Sell at Pivotal Research
Pivotal Research analyst Ajay Jain upgraded United Natural Foods to Hold from Sell, stating that he sees near-term risks as better reflected in the stock's valuation with the shares down about 66% since late July when the Supervalu deal was announced. He reduced his price target on United Natural Foods shares to $14 from $18, adding that he remains "extremely cautious overall" about on United Natural's increased risk profile.
ROST Ross Stores
$94.18

0.58 (0.62%)

01/24/19
LOOP
01/24/19
NO CHANGE
Target $105
LOOP
Buy
Ross Stores price target raised to $105 from $100 at Loop Capital
Loop Capital analyst Laura Champine raised her price target on Ross Stores to $105 and kept her Buy rating, saying she is increasing her store growth assumptions and updating her expense leverage forecasts. The analyst notes that the working class customers of Ross Stores are benefiting from wage inflation and a healthy job market, forecasting the company to continue taking market share. Champine adds that while Ross Stores has outperformed S&P500 this month, its resilient business model justifies the Buy rating.
11/21/18
DADA
11/21/18
NO CHANGE
Target $84
DADA
Neutral
Ross Stores price target lowered to $84 from $96 at DA Davidson
DA Davidson analyst John Morris lowered his price target on Ross Stores to $84 and kept his Neutral rating, saying that while the company beat Q3 earnings by a penny, its gross margins weakened and average unit retail metric was flat. The analyst notes that the 3% increase in comps was driven by "strength in the Midwest and Florida, as well as top-performing categories such as men's, shoes, and accessories". However, Morris also anticipates Ross Stores to remain challenged by the ongoing freight and labor cost headwinds, reducing his FY18 and FY19 EPS view by 7c to $4.19 and $4.45 respectively.
01/16/19
FBCO
01/16/19
NO CHANGE
Target $50
FBCO
Neutral
Nordstrom price target lowered to $50 from $55 at Credit Suisse
Credit Suisse analyst Michael Binetti lowered his price target for Nordstrom (JWN) to $50 from $55 on weak full-price holiday adding to already clearance filled January. With Nordstrom adding to industry markdown issues, the analyst sees negative reads for J.C. Penney (JCP), Kohl's (KSS), Gap (GPS), but positive for Burlington Stores (BURL), Ross Stores (ROST), and TJX (TJX). Binetti reiterates a Neutral rating on Nordstrom shares.
11/21/18
MKMP
11/21/18
NO CHANGE
Target $95
MKMP
Buy
Ross Stores price target lowered to $95 from $98 at MKM Partners
MKM Partners analyst Roxanne Meyer lowered her price target on Ross Stores to $95, saying that while the company had a slight beat on Q3 earnings, the quarter was seen as "disappointing" relative to outsized comp gains at some of its peers. The analyst states that the 3-year comps stack of 14% was up from 13% in Q2 and also above 13% of Marmaxx. However, Meyer also believes that the 3% rise in comps is not enough to offset the higher expense pressure in the second half of 2018 coming from wage and freight inflation. Longer term, the analyst keeps her Buy rating on Ross Stores.
CBAY CymaBay
$13.31

-0.1 (-0.75%)

02/22/19
LEER
02/22/19
INITIATION
Target $22
LEER
Outperform
CymaBay initiated with an Outperform at SVB Leerink
SVP Leerink analyst Pasha Sarraf initiated CymaBay with an Outperform rating and $22 price target, telling investors in a research note that the company is demonstrating "impressive" efficacy and safety profile in PBC and pre-clinically in NASH. Sarraf says he is positive on the immunology sector with its diverse indications, continuous innovation, and deep expertise, and is looking long for opportunities in challenging immuno-metabolism and metabolism sectors, in areas like NASH, obesity and diabetes.
02/20/19
PIPR
02/20/19
NO CHANGE
Target $30
PIPR
Overweight
'Underwhelming' Intercept data hurts CymaBay bear thesis, says Piper Jaffray
One of the major constituents of the CymaBay Therapeutics (CBAY) bear thesis has been that pricing for Intercept Pharmaceuticals' (ICPT) Ocaliva would get cut significantly with success in nonalcoholic steatohepatitis and consequently lower the eventual market opportunity for CymaBay's seladelapar in primary biliary cholangitis, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst, however, believes Intercept's Ocaliva data in NASH yesterday was "underwhelming" as the "fibrosis improvement was mild, no significant effect on NASH was observed, and worrisome safety and tolerability issues remain." Questions regarding the commercial viability of Ocaliva in NASH are now likely to persist, says Van Buren. He now believes Intercept will have to target the most severe patients, "significantly narrowing" the drug's addressable population. This should lead to more stable Ocaliva pricing than many currently assume and keep seladelpar's $750M-plus market opportunity in PBC "largely" intact, contends the analyst. Bottom line is that a major constituent of the CymaBay bear thesis has now been removed, he writes. Van Buren keeps an Overweight rating on the shares with a $30 price target. CymaBay Therapeutics closed yesterday up 34c to $10.29.
03/01/19
PIPR
03/01/19
NO CHANGE
Target $30
PIPR
Overweight
Piper Jaffray loves the setup for CymaBay shares into NASH data
CymaBay's Seladelpar has made "tremendous progress" in primary biliary cholangitis over the past year its competitive positioning continues to improve, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Further, the analyst believes the drug's nonalcoholic steatohepatitis opportunity is not currently being factored into the existing valuation. The analyst expects to receive topline data from the ongoing Phase IIb trial of seladelpar in NASH next quarter. If successful, it could "multiply" the $750M PBC opportunity in his model, Van Buren says in a research note titled "We Love The Setup Of CBAY Here; Reiterate The Overweight." He keeps a $30 price target on CymaBay shares.
02/06/19
02/06/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nasdaq (NDAQ) initiated with a Buy at Argus. 2. Marinus Pharmaceuticals (MRNS) initiated with an Outperform at Leerink. 3. PolyOne (POL) initiated with a Buy at Buckingham. 4. Marathon Petroleum (MPC) initiated with an Outperform at Macquarie. 5. CymaBay (CBAY) initiated with a Neutral at B. Riley FBR.This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
HZNP Horizon Pharma
$27.22

-0.78 (-2.79%)

01/02/19
PIPR
01/02/19
NO CHANGE
PIPR
Piper calls Horizon top 2019 growth idea in Specialty Pharmaceuticals
Piper Jaffray analyst David Amsellem calls Horizon Pharma (HZNP) his top "growth oriented/GARP idea" for 2019. The company offers high asset quality, visibility into significant longer-term EBITDA growth, and manageable debt levels that enable significant business development flexibility, Amsellem tells investors in a research note. He believes the Specialty Pharmaceuticals group is well positioned to perform more in-line with the broader therapeutics and overall healthcare spaces in 2019, or "certainly better than what we have seen in recent years." The analyst names Bausch Health (BHC), a stock he upgraded this morning to Overweight, his top "de-leveraging/defensive pick" for 2019. Further, Amsellem's top "development-stage picks" for 2019 are Cara Therapeutics (CARA) and Revance Therapeutics (RVNC).
03/01/19
JEFF
03/01/19
NO CHANGE
Target $34
JEFF
Buy
Horizon Pharma price target raised to $34 from $28 at Jefferies
Jefferies analyst David Steinberg raised his price target for Horizon Pharma to $34 after the company announced positive Phase 3 data for teprotumumab in treating thyroid eye disease. Based on the "strong" data, teprotumumab has the potential to be a disease-modifying therapy for active thyroid eye disease, Steinberg tells investors in a research note. He sees the drug generating $500M-plus in peak sales and keeps a Buy rating on Horizon Pharma.
03/01/19
MZHO
03/01/19
NO CHANGE
Target $27
MZHO
Neutral
Horizon Pharma price target raised to $27 from $21 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Horizon Pharma to $27 saying the positive teprotumumab data should support drug approval in 2020. The analyst, however, does not view the shares as undervalued and reiterates a Neutral rating on Horizon Pharma.
03/01/19
JMPS
03/01/19
NO CHANGE
Target $38
JMPS
Outperform
Horizon Pharma price target raised to $38 from $26 at JMP Securities
JMP Securities analyst Donald Ellis raised his price target on Horizon Pharma to $38 from $26 after the company released top-line data for teprotumumab for the treatment of thyroid eye disease, stating that those data provide the pathway for a BLA submission in mid-2019. The analyst, who expects patients and physicians will be highly motivated to use Tepro immediately upon approval, now models a potential Tepro launch in 2020. Ellis keeps an Outperform rating on Horizon shares.
BAND Bandwidth
$57.75

0.88 (1.55%)

10/31/18
ADAM
10/31/18
NO CHANGE
Target $60
ADAM
Buy
Bandwidth price target raised to $60 from $44 at Canaccord
Canaccord analyst Richard Davis raised his price target on Bandwidth to $60 from $44 following Q3 results. The analyst noted an unexpected improvement in margins and the growth in its CPaaS revenues. He believes the company's fundamental momentum could let the stock tack on gains in the coming year despite its run in 2018. He said the management team is not flashy but is executing flawlessly. In a good scenario, he can see the shares appreciating 30-50%, said Davis, who reiterated his Buy rating on Bandwith.
07/02/18
07/02/18
DOWNGRADE
Target $40

Equal Weight
Bandwidth downgraded to Equal Weight after 90% jump since IPO at Morgan Stanley
As previously reported, Morgan Stanley analyst Meta Marshall downgraded Bandwidth to Equal Weight from Overweight, arguing that its IPO price embedded a "meaningful discount" but that the stock's 90% appreciation since then has closed the gap with the peer group. While Bandwidth shares still trade at a bit of a discount, the company likely needs larger beats to continue closing that gap, said Marshall. However, she thinks beats to expectations are more likely in 2019 than the rest of 2018 as investments to drive them are just being made. Marshall keeps a $40 price target on Bandwidth shares.
09/04/18
KEYB
09/04/18
NO CHANGE
Target $42
KEYB
Overweight
SendGrid price target raised to $42 from $32 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for SendGrid (SEND) to $42 from $32 as he believes 2018 marks an inflection year for cloud software APIs that are poised to go ubiquitous across the broader enterprise over the next five years. The analyst has increasing confidence in the upside levers to cloud software API business models like Amazon (AMZN), Twilio (TWLO), Bandwidth (BAND), and SendGrid. Bracelin reiterates an Overweight rating on SendGrid shares.
09/04/18
KEYB
09/04/18
NO CHANGE
Target $64
KEYB
Overweight
Bandwidth price target raised to $64 from $45 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for Bandwidth (BAND) to $64 from $45 as he believes 2018 marks an inflection year for cloud software APIs that are poised to go ubiquitous across the broader enterprise over the next five years. The analyst has increasing confidence in the upside levers to cloud software API business models like Amazon (AMZN), Twilio (TWLO), Bandwidth, and SendGrid (SEND). Bracelin reiterates an Overweight rating on Bandwidth shares.
EXAS Exact Sciences
$87.62

-1.29 (-1.45%)

02/26/19
02/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exact Sciences (EXAS) upgraded to Buy from Neutral at Goldman Sachs by analyst Patrick Donnelly, who said the current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018. Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst said. 2. Siemens (SIEGY) upgraded to Overweight from Neutral at JPMorgan by analyst Andreas Willi, who sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." 3. Kadmon (KDMN) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who assigned a 50% probability to KD-025 in chronic graft versus host disease with an unadjusted ~$900M market opportunity. However, upside to the stock will depend on quality of the data likely, Karnauskas said. 4. EverQuote (EVER) upgraded to Buy following Q4 beat at BofA/Merrill by analyst Mat Schindler, who said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive. 5. Ally Financial (ALLY) upgraded to Buy from Hold at Sandler O'Neill by analyst Christopher Donat, who said he believes Ally's near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
GSCO
02/26/19
UPGRADE
Target $120
GSCO
Buy
Goldman upgrades Exact Sciences to Buy, calls 'must-own growth stock'
Goldman Sachs analyst Patrick Donnelly upgraded Exact Sciences to Buy and raised his price target for the shares to $120 from $85. The current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018, Donnelly tells investors in a research note. He views the Cologuard product cycle as the "most compelling across all of diagnostics." Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst contends. Donnelly believes the company's story is only strengthening and sees the stock as poised to continue its outperformance moving forward.
02/26/19
GSCO
02/26/19
UPGRADE
Target $120
GSCO
Buy
Exact Sciences upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Patrick Donnelly upgraded Exact Sciences to Buy and raised his price target for the shares to $120 from $85. The stock closed yesterday down 28c to $91.76. The ramp of Cologuard remains in the early stages with acceleration ahead, and Exact's pipeline optionality is underappreciated, Donnelly tells investors in a research note.
03/04/19
BARD
03/04/19
NO CHANGE
Target $102
BARD
Outperform
Aetna lowering of screening age positive for Exact Sciences, says Baird
CVS Health (CVS) unit Aetna on Friday revised its policy to state that colorectal cancer screening is considered medically necessary for average-risk persons aged 45 years and older when recommended by their physician, Baird analyst Catherine Ramsey Schulte tells investors in a research note. Aetna's previous version covered for average-risk persons beginning at age 50 years, the analyst points out. While admitting further uptake in ages 45-49 will require medical education among doctors, Ramsey Schulte views Aetne'a update as "incrementally positive" for Exact Sciences. She keeps an Outperform rating on the shares with a $102 price target. The stock in early trading is up 1% to $93.57.

TODAY'S FREE FLY STORIES

21:25
03/25/19
03/25
21:25
03/25/19
21:25
General news
Fed's Rosengren warned that U.S. Q1 growth is likely to be weak »

Fed's Rosengren…

BBBY

Bed Bath & Beyond

$13.87

0.17 (1.24%)

20:44
03/25/19
03/25
20:44
03/25/19
20:44
Periodicals
Activist firms seek to replace Bed Bath & Beyond board, CEO, WSJ says »

Activist funds -Legion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Apr

RTN

Raytheon

$180.58

-0.82 (-0.45%)

, BA

Boeing

$370.52

8.37 (2.31%)

20:36
03/25/19
03/25
20:36
03/25/19
20:36
Hot Stocks
Raytheon kill vehicle hits ICBM target in first dual-salvo test »

For the first time, the…

RTN

Raytheon

$180.58

-0.82 (-0.45%)

BA

Boeing

$370.52

8.37 (2.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

20:35
03/25/19
03/25
20:35
03/25/19
20:35
General news
The "Summary of Opinions" from the BoJ's March meeting »

The "Summary of…

WHD

Cactus

$36.03

1.225 (3.52%)

20:27
03/25/19
03/25
20:27
03/25/19
20:27
Hot Stocks
Cactus VP of Operations sells 229K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$56.67

-0.065 (-0.11%)

, MKC

McCormick

$143.88

1.58 (1.11%)

20:25
03/25/19
03/25
20:25
03/25/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$56.67

-0.065 (-0.11%)

MKC

McCormick

$143.88

1.58 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 27

    Mar

CRTO

Criteo

$21.99

-3.4 (-13.39%)

20:19
03/25/19
03/25
20:19
03/25/19
20:19
Downgrade
Criteo rating change at KeyBanc »

Criteo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

20:02
03/25/19
03/25
20:02
03/25/19
20:02
Periodicals
Samsung sees weaker environment for display, memory in Q1, Bloomberg says »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$370.52

8.37 (2.31%)

19:51
03/25/19
03/25
19:51
03/25/19
19:51
Hot Stocks
U.S. MDA and Boeing Complete Historic Missile Defense Test »

The U.S. Missile Defense…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

MCD

McDonald's

$185.66

-1.11 (-0.59%)

19:49
03/25/19
03/25
19:49
03/25/19
19:49
Periodicals
McDonald's purchase price of Dynamic Yield above $300M, Bloomberg says »

The purchase of Dynamic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 28

    May

SSNLF

Samsung

$0.00

(0.00%)

19:32
03/25/19
03/25
19:32
03/25/19
19:32
Periodicals
Breaking Periodicals news story on Samsung »

Samsung sees Q1 below…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWR

American States Water

$71.51

0.505 (0.71%)

19:22
03/25/19
03/25
19:22
03/25/19
19:22
Hot Stocks
American States Water CEO sells 12.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$56.35

-1.38 (-2.39%)

19:10
03/25/19
03/25
19:10
03/25/19
19:10
Hot Stocks
Methanex confirms receipt of director nominees notice from M&G »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

, SAEX

SAExploration

$4.03

0.13 (3.33%)

18:55
03/25/19
03/25
18:55
03/25/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

DOWN AFTER EARNINGS:…

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

SAEX

SAExploration

$4.03

0.13 (3.33%)

IQ

iQIYI

$24.01

-0.86 (-3.46%)

MYOK

MyoKardia

$51.87

-2.44 (-4.49%)

CTMX

CytomX Therapeutics

$10.76

0.33 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 21

    May

  • 27

    Mar

HPQ

HP Inc.

$18.97

-0.4 (-2.07%)

18:48
03/25/19
03/25
18:48
03/25/19
18:48
Periodicals
HP lawyer tells court Autonomy's Lynch inflated sales data, Reuters says »

A lawyer for HP told a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

PEGA

Pegasystems

$63.61

-0.27 (-0.42%)

18:45
03/25/19
03/25
18:45
03/25/19
18:45
Hot Stocks
Pegasystems CEO: We are massively changing our marketing strategy »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

SMTC

Semtech

$52.59

-0.38 (-0.72%)

18:32
03/25/19
03/25
18:32
03/25/19
18:32
Hot Stocks
Semtech CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TMO

Thermo Fisher

$268.89

5.015 (1.90%)

18:24
03/25/19
03/25
18:24
03/25/19
18:24
Hot Stocks
Thermo Fisher CEO: We have a very disciplined M&A process »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

18:24
03/25/19
03/25
18:24
03/25/19
18:24
Periodicals
Parliament forces votes on Brexit plan options, Bloomberg reports »

Lawmakers of U.K.…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.99

-0.56 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$185.66

-1.11 (-0.59%)

18:23
03/25/19
03/25
18:23
03/25/19
18:23
Hot Stocks
McDonald's to acquire Dynamic Yield, terms not stated »

McDonald's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 28

    May

BA

Boeing

$370.52

8.37 (2.31%)

18:22
03/25/19
03/25
18:22
03/25/19
18:22
Periodicals
Boeing software fix to prevent repeated activiation of MCAS, Reuters says »

A Boeing software repair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ACHC

Acadia

$29.47

-0.59 (-1.96%)

17:58
03/25/19
03/25
17:58
03/25/19
17:58
Hot Stocks
Acadia says President Brett Turner leaving by mutual agreement »

Brent Turner, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.78

-2.33 (-1.22%)

17:41
03/25/19
03/25
17:41
03/25/19
17:41
Recommendations
Apple analyst commentary at Piper Jaffray »

Apple price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

ZFGN

Zafgen

$2.70

-0.15 (-5.26%)

17:38
03/25/19
03/25
17:38
03/25/19
17:38
Hot Stocks
Armistice Capital reports 5.6% passive stake in Zafgen »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$268.56

0.27 (0.10%)

17:36
03/25/19
03/25
17:36
03/25/19
17:36
Hot Stocks
Northrop Grumman awarded $245.05M Navy contract modification »

Northrop Grumman has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.